Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-1002 in Duchenne Muscular Dystrophy
NCT06304064Phase 2Completed
- Sponsor
- Capricor Therapeutics
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of deramiocel in Duchenne muscular dystrophy (DMD), sponsored by Capricor Therapeutics. Started Jun 2018; status: completed.
02
Drugs
deramiocel
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06304064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06304064.